肠促胰岛素
食欲
内分泌学
医学
内科学
受体
减肥
糖尿病
兴奋剂
神经科学
心理学
肥胖
2型糖尿病
作者
Sophie Buller,Clémence Blouet
出处
期刊:American Journal of Physiology-endocrinology and Metabolism
[American Physiological Society]
日期:2024-02-21
标识
DOI:10.1152/ajpendo.00250.2023
摘要
Incretin-based pharmacotherapies provide novel efficient and safe therapeutic options to curb appetite and produce weight loss in obese patients. Delivered systemically, these molecules produce pleiotropic metabolic benefits, but the target sites mediating their weight-suppressive action are located within the brain. Recent research has increased our understanding of the neural circuits and behavioural mechanisms involved in the anorectic and metabolic consequences of glucagon-like peptide 1 (GLP-1)-based weight loss strategies, yet little is known about how these drugs access their functional targets in the brain to produce sustained weight loss. The majority of brain cells expressing incretin receptors are located behind the blood-brain barrier, shielded from the circulation and fluctuations in the availability of peripheral signals, which is a major challenge for the development of CNS-targeted therapeutic peptides. GLP-1 receptor (GLP-1R) agonists with increased half-life and enhanced therapeutic benefit do not cross the blood-brain-barrier, yet they manage to access discrete brain sites relevant to the regulation of energy homeostasis. In this review, we give a brief overview of the different routes for peptide hormones to access the brain. We then examine the evidence informing the routes employed by incretins and incretin receptor agonists to access brain targets relevant for their appetite and weight-suppressive actions. We highlight existing controversies and suggest future directions to further establish the functionally relevant access routes for GLP-1-based weight loss compounds, which might guide the development and selection of the future generation of incretin receptor polypharmacologies.
科研通智能强力驱动
Strongly Powered by AbleSci AI